Silvia G Priori MD PhD

Similar documents
Pearls of the ESC/ERS Guidelines 2015 Channelopathies

Secondary prevention of sudden cardiac death

What Every Physician Should Know:

Jean François Leclercq Department of Rythmology Private Hospital of Parly 2 - Le Chesnay F

Arrhythmias Focused Review. Who Needs An ICD?

Synopsis of Management on Ventricular arrhythmias. M. Soni MD Interventional Cardiologist

Syncope in patients with inherited arrhythmogenic syndromes. Is it enough to justify ICD implantation?

2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline. Top Ten Messages. Eleftherios M Kallergis, MD, PhD, FESC

Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know

that number is extremely high. It s 16 episodes, or in other words, it s 14, one-four, ICD shocks per patient per day.

IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT JANUARY 24, 2012

Sudden death as co-morbidity in patients following vascular intervention

The implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease

Tachycardia Devices Indications and Basic Trouble Shooting

ΤΙ ΠΡΕΠΕΙ ΝΑ ΓΝΩΡΙΖΕΙ ΟΓΕΝΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ ΓΙΑ ΤΙΣ ΔΙΑΥΛΟΠΑΘΕΙΕΣ

Prophylactic ablation

Strength and weakness of genetic testing in clinical routine.

FANS Paediatric Pathway for Inherited Arrhythmias*

Index. cardiacep.theclinics.com. Note: Page numbers of article titles are in boldface type.

The Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia

The patient with (without) an ICD and heart failure: Management of electrical storm

Heart Failure Challenges and Unmet needs

Invasive Risk Stratification: When is it needed?

Ventricular tachycardia and ischemia. Martin Jan Schalij Department of Cardiology Leiden University Medical Center

ICD. Guidelines and Critical Review of Trials. Win K. Shen, MD Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic Arizona Torino 2011

Endpoints When Treating VT/VF in Patients with ICDs Programming Wojciech Zareba, MD, PhD

Name of Presenter: Marwan Refaat, MD

Arrhythmias (II) Ventricular Arrhythmias. Disclosures

SUDDEN CARDIAC DEATH(SCD): Definition

Subcutaneous Implantable Cardioverter Defibrillator (ICD) System

Do All Patients With An ICD Indication Need A BiV Pacing Device?

The patient with electric storm

Drugs Controlling Myocyte Excitability and Conduction at the AV node Singh and Vaughan-Williams Classification

Sudden cardiac death: Primary and secondary prevention

Investigating the family after a sudden cardiac death. Dr Catherine Mercer Consultant Clinical Geneticist, Wessex

Sudden Cardiac Death and Asians Disclosures

SUDDEN CARDIAC DEATH(SCD): Definition

Patient Resources: Cardiac Channelopathies

WINDLAND SMITH RICE SUDDEN DEATH GENOMICS LABORATORY

Plotse hartdood & genetica

SPORTS AND EXERCISE ADVICE IN PATIENTS WITH ICD AND PPM

Ventricular Tachycardia Ablation. Saverio Iacopino, MD, FACC, FESC

Who does not need a primary preventive ICD?

Genetic testing in Cardiomyopathies

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Tachycardias II. Štěpán Havránek

What You Should Know About Subcutaneous and Transvenous ICD

Ενδείξεισ εμφύτευςησ απινιδωτή ςτην «γκρίζα ζώνη» Γεώργιοσ Ανδρικόπουλοσ, MD, PhD, Αν. Δ/ντήσ Καρδιολογικήσ Κλινικήσ ΓΝΑ «Ερρίκοσ Ντυνάν»

Syncope in Heart Failure Patients How to judge and treat? Jean-Claude Deharo, MD, FESC Marseilles, France

Πρόληψη του ΑΚΘ σε ασθενείς με μη-ισχαιμική μυοκαρδιοπάθεια:

Implantable Cardioverter Defibrillator (ICD)

Ventricular arrhythmias

Recurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm

ΔΠΔΜΒΑΣΙΚΗ ΘΔΡΑΠΔΙΑ ΚΟΙΛΙΑΚΩΝ ΑΡΡΤΘΜΙΩΝ

Abbreviation List: 2017 by the American Heart Association, Inc. and the American College of Cardiology Foundation. 1

Clinical Cardiac Electrophysiology

Silvia G Priori MD PhD

Where Does the Wearable Cardioverter Defibrillator (WCD) Fit In?

Exercise guidelines in athletes with isolated repolarisation abnormalities and structurally normal heart.

New scientific documents from EHRA Management of patients with defibrillator shocks

What is New in CPVT? Diagnosis Genetics Arrhythmia Mechanism Treatment. Andreas Pflaumer

Editorial TREATMENT OF SUDDEN CARDIAC DEATH SURVIVORS: DRUGS VERSUS DEVICE

Ventricular arrhythmias in acute coronary syndromes. Dimitrios Manolatos, MD, PhD, FESC Electrophysiology Lab Evaggelismos General Hospital

What s new in my specialty?

Treatment of VT of Purkinje fiber origin: ablation targets and outcome

Index. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.

Antiarrhythmic Drugs and Ablation in Patients with ICD and Shocks

The Role of Defibrillator Therapy in Genetic Arrhythmia Syndromes

ICD THERAPIES: are they harmful or just high risk markers?

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Ablative Therapy for Ventricular Tachycardia

Prevention of Sudden Death in ARVC

Risk Stratification of Sudden Cardiac Death

Inherited Arrhythmia Syndromes

Device Update Implantable Cardioverter Defibrillator (ICD) 박상원

When VF is the endpoint, wait and see is not always the best option.

Idiopathic Ventricular Tachycardia Need for an Update in EHRA/HRS Consensus?

Asymptomatic Long QT. Prof. Dr. Martin Borggrefe Mannheim

Pattarapong Makarawate MD, FHRS Assistant Professor. Division Of Cardiology Faculty of Medicine, Khon Kaen University

The Role of ICD Therapy in Cardiac Resynchronization

NAAMA s 24 th International Medical Convention Medicine in the Next Decade: Challenges and Opportunities Beirut, Lebanon June 26 July 2, 2010

Tailored therapy in long QT syndrome

Journal of the American College of Cardiology Vol. 37, No. 2, by the American College of Cardiology ISSN /01/$20.

Primary prevention ICD recipients: the need for defibrillator back-up after an event-free first battery service-life

Εμφύτευση απινιδωτών για πρωτογενή πρόληψη σε ασθενείς που δεν περιλαμβάνονται στις κλινικές μελέτες

Arrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh

Rhythm Control: Is There a Role for the PCP? Blake Norris, MD, FACC BHHI Primary Care Symposium February 28, 2014

Prevention of sudden cardiac death: With an emphasis on sudden cardiac death from ventricular arrhythmias

Destructive Device Removal - Sparks and Deletion of Therapy History From an Implantable Cardioverter Defibrillator. Case Reports

Are there low risk patients in Brugada syndrome?

CLINICAL CARDIAC ELECTROPHYSIOLOGY Maintenance of Certification (MOC) Examination Blueprint

עדכונים באלקטרופיזיולוגיה Electrophysiology Unit Soroka University Medical Center Faculty of Health Sciences Ben-Gurion University of the Negev

Clinical and Molecular Characterization of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia

Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides

Rate and Rhythm Control of Atrial Fibrillation

Devices and Other Non- Pharmacologic Therapy in CHF. Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine

Management of Coronary Artery Spasm

ICD Therapy. Disclaimers

Electrical Storm in Coronary Artery Disease. Saeed Oraii MD, Cardiologist Interventional Electrophysiologist Tehran Arrhythmia Clinic July 2016

EVALUATION OF THE ATHLETE. Karen Stout, MD Professor, Medicine and Pediatrics University of Washington

Transcription:

The approach to the cardiac arrest survivor Silvia G Priori MD PhD Molecular Cardiology, IRCCS Fondazione Salvatore Maugeri Pavia, Italy AND Leon Charney Division of Cardiology, Cardiovascular Genetics Program, Langone Medical Center, New York University School of Medicine, New York, USA

The topic of this presentation will be discussed in light of the recommendations provided by the ESC 2015 Guidelines for the prevention of SCD

Myerburg s Paradox

Myerburg s Paradox In the general population the incidence of Cardiac Arrest is low..however, a high percentage of SCD victims belong to this category!

Cardiac arrest in the structurally intact heart Sudden arrhythmic death in the absence of structural heart disease is an uncommon event. However, data from large series of patients resuscitated from cardiac arrest and necropsy data from victims of sudden death indicate that there is no evidence of structural heart disease in 5% of victims of sudden death. IVF is a diagnosis of exclusion. Therefore, it is of pivotal importance to define the conditions that have to be excluded as well as the most appropriate techniques for excluding them. Circulation. 1997; 95: 265-272

Diagnostic investigations required in a survivor of cardiac arrest If all the mandatory investigations are negative, the diagnosis of Idiopathic Ventricular Fibrillation can be established Survivors of Out-of-Hospital Cardiac Arrest With Apparently Normal Heart Need for Definition and Standardized Clinical Evaluation Consensus Statement of the Joint Steering Committees of the Unexplained Cardiac Arrest Registry of Europe* and of the Idiopathic Ventricular Fibrillation Registry of the United States Circulation. 1997; 95: 265-272

Minimal abnormalities compatible with the diagnosis of IVF Survivors of Out-of-Hospital Cardiac Arrest With Apparently Normal Heart Need for Definition and Standardized Clinical Evaluation Consensus Statement of the Joint Steering Committees of the Unexplained Cardiac Arrest Registry of Europe* and of the Idiopathic Ventricular Fibrillation Registry of the United States Circulation. 1997; 95: 265-272

A strong call for autopsy in SCD victims. This recommendation is established to the benefit of family members of young SCD victims.

Cardiac arrest with a structurally normal heart Survivors of cardiac arrest with a structurally normal heart have a Class I indication for the ICD Ablation of a triggering PVC is indicated with a Class I if performed by experienced operators

Cardiac arrest with a structural heart disease (1) Identification and correction of the reversible causes Optimal Medical Treatment for the underlying disease Reasonable expectation of survival with a good functional status at 1 year

Cardiac arrest with a structural heart disease (2) Secondary prevention of Cardiac Arrest: AVID;CASH;CIDS Connolly SJ, et al Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 2000;21:2071 2078.

Opitimizing management beyond the ICD: Ischemic substrate When acute ischemia precedes VF, there is evidence that coronary revascularization improves outcome. If VA are present, Amiodarone may be used to reduce symptoms BUT sodium channel blockers are contraindicated

CA Survivors with HF: ICD or CRT-D? In the absence of specific data for patients in secondary prevention of CA.the decision on implant of CRT-D should be based on the recommendations for primary prevention.

CA Survivors with HF and sustained VT: How to manage beyond the ICD? In the absence of specific data for HF patients in secondary prevention of CA.management of symptomatic sustained VT should be based on recommendation for HF patients: OPTIMIZATION OF HF THERAPY AMIODARONE/ ABLATION AMIODARONE/ ABLATION

Survivors of Cardiac Arrest with HCM CLASS I RECOMMENDATION FOR ICD IMPLANTATION IN HCM SURVIVORS OF CARDIAC ARREST ALSO EXTENDS TO THE PEDIATRIC POPULATION: SUSTAINED VT AND REPEATED ICD SHOCKS MAY BE MANAGED WITH AMIODARONE, BETA BLOCKERS OR CATHETER ABLATION.

Survivors of CA with ARVC The ability of sotalol, beta blockers and amiodarone to reduce symptomatic ventricular arrhythmias (PVCs, nsvt, Sust VT) is still debated. While consensus exists on their inability to prevent CA. In young patients, amiodarone presents the challenge of adverse events, so it may not be the first choice agent in young patients implanted with ICD and ablation might be preferable.

Cardiomyopathies of miscellaneous origin In cardiomyopathies with miscellaneous origin (Amyloid, Chagas, Restrictive, LV non Compaction..) there is a global recommendation to implant an ICD in patients with life-threatening arrhythmias and in survivors of ICD. This recommendation is not based on evidence, but on the lack of effective alternatives.

Survivors of CA with Long QT Syndrome According to the recommendation, LQTS survivors of a CA should get an ICD on top of beta blockers. Left cardiac sympathetic denervation may be an option for patients who refuse an ICD or when there is a contraindication to the ICD

Cumulative Survival (%) Survival in LQTS according to genotype 100 90 80 70 60 50 40 30 20 10 p=0.007 Genotype LQT1: LQT2: LQT3: LQT1 LQT2 LQT3 0 0 10 20 Age (years) 30 40 Priori SG et al NEJM 2003

Cardiac event free survival Cardiac Events on Beta Blockers in LQTS 1.0 0.9 0.8 0.7 0.6 LQT1 0.5 0.4 0.3 0.2 LQT3 LQT2 0.1 0.0 0 p<0.0001 5 10 Follow up (years) 15 20 Priori et al. JAMA 2004

EXCEPTION TO THE RECOMMENDATIONS?? In selected patients with LQTS surviving a cardiac arrest that occurred when the patient was not taking beta blockers, it may be reasonable to hold on ICD implantation and start beta blockers: Pediatric LQT1 patients are on top of such a list because of the high rate of side effects of the ICD in children and for the good response of LQT1 patients to beta blockers

How to manage a survivor of CA with diagnosis of Brugada Syndrome? How to manage an electrical storm/ repeated ICD shocks?

How to manage a survivor of CA with diagnosis of Catecholaminergic Polymorphic VT (CPVT)?

Event-free survival Why in CPVT do we not recommend waiting to implant an ICD if the cardiac arrest occurred without beta blocker therapy? 100 80 Age 10: 30% of pts with symptoms 60 40 Age 40: 79% of pts with symptoms 20 0 0 10 20 30 40

Event-free survival Why in CPVT do we not recommend waiting to implant an ICD if the cardiac arrest occurred without beta blocker therapy? 100 80 Age 10: 30% of pts with symptoms 60 40 SEVERE PROGNOSIS= Age 40: 79% of pts with symptoms MALIGNANT DISEASE 20 0 0 10 20 30 40

Cardiac event-free survival Why in CPVT do we not recommend waiting to implant an ICD if the cardiac arrest occurred without beta blocker therapy? 100 80 60 40 20 0 0 5 10 Time on therapy (years) N= 110 patients with -blockers Mean follow-up of 4 years 26% with recurrences N= 81 patients with, n= 21 without -blockers Mean follow-up of 8 years 27% with recurrences Priori et al Hayashi et al

Cardiac event-free survival Why in CPVT do we not recommend waiting to implant an ICD if the cardiac arrest occurred without beta blocker therapy? 100 80 60 40 20 0 0 5 10 Time on therapy (years) Poor response To beta blockers! N= 110 patients with -blockers Mean follow-up of 4 years 26% with recurrences N= 81 patients with, n= 21 without -blockers Mean follow-up of 8 years 27% with recurrences Priori et al Hayashi et al

Q&A Idiopathic Ventricular Fibrillation is a diagnosis established: 1. When the autopsy cannot be performed 2. When there is no clinical information on the clinical history of the patient 3. When ECG, Holter, Echocardiogram and Exercise stress test are negative 4. When a large set of tests to rule out the most common causes of SCD is performed and is negative

Q&A Which of the following is true? 1. Children surviving a cardiac arrest with long QT syndrome have a contraindication to the ICD 2. An ICD is indicated for survivors of cardiac arrest only when an ischemic substrate is documented 3. Most survivors of CA are candidates for cardiac resynchronization 4. The strategies to reduce ICD shocks in survivors of CA implanted with an ICD largely depend on the underlying disease

Conclusions (1) SCD occurs in association with a variety of conditions: the substrate underlying the arrhythmic event influences the management of survivors. SCD occurring in the absence of structural heart disease is called IVF: a definite set of investigations is required to exclude the presence of an underlying disease, thus leading to the diagnosis of IVF In victims of unexplained SCD, an autopsy with molecular autopsy is indicated

Conclusions (2) ICD in secondary prevention of CA is indicated in the vast majority of CA survivors, including children. Strategies for reduction of ICD shocks and prevention of electrical storms in CA survivors are tailored to the arrhythmogenic substrate.